Trademark Search in Canada

ADN ADIENNE PHARMA & BIOTECH

View On IC.GC.CA

REGISTERED

on 26 Apr 2023

Last Applicant/ Owned by

ADIENNE S.R.L.

Via Galileo Galilei, n. 19Caponago (MB)I-20867

Serial Number

2018528 filed on 4^th Mar 2020

Registration Number

TMA1177081 registered on 26^th Apr 2023

Registration expiry Date

11^th May 2026

Correspondent Address

SMART & BIGGAR LP

1000 RUE DE LA GAUCHETIERE OUESTBUREAU 3300MONTREAL

QUÉBEC

H3B4W5

ADN ADIENNE PHARMA & BIOTECH

Trademark usage description

pharmaceutical preparations, namely pharmaceutical products used for conditioning treatment prior to haematopoietic progenitor cell transplantation an Read More

Vienna Information

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 19

Letters overlappingLettres se chevauchant

24 . 17 . 25

Other signs, notations or symbolsAutres signes, notations ou symboles

27 . 5 . 4

Letters embellished or decorated with a drawing or composed of a collection of drawingsLettres enjolivées ou ornées d'un dessin ou composées par un assemblage de dessins

27 . 5 . 22

Monograms formed of intertwined, overlapping or otherwise combined lettersMonogrammes formés par des lettres enlacées, se chevauchant ou combinées autrement

Classification Information

Class [005]
Pharmaceutical preparations, namely pharmaceutical products used for conditioning treatment prior to haematopoietic progenitor cell transplantation and prior to haematopoietic stem cell transplantation, for the treatment of blood disorders, for the prevention and treatment of cancer, for the prevention and treatment of immune system-related diseases and disorders, namely, graft-versus-host disease, aplastic anemia, immunodeficiency, autoimmune diseases; pharmaceutical preparations, namely antibodies used as pharmaceutical preparations with anti-inflammatory action, monoclonal antibodies for neutralizing components of the complement system, monoclonal antibodies and antibody mixtures for medical use, namely, diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, monoclonal antibodies for immunomodulatory treatments; pharmaceutical preparations for the prevention of ischemia/reperfusion injury associated with solid, organ transplantation, for the treatment of graft-versus-host disease and severe aplastic anemia; pharmaceutical preparations, namely immunosuppressants; pharmaceutical preparations, namely, human vaccines; pharmaceutical preparations, namely, vaccine adjuvants; material for stopping teeth, dental wax; preparations for destroying vermin; fungicides, herbicides.

Classification kind code

Mark Details

Serial Number

2018528

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 14^th Jul 2021	Search Recorded
Submitted for opposition 20 on 14^th Jul 2021	Examiner's First Report
Submitted for opposition 223 on 14^th Jul 2021	Total Provisional Refusal
Submitted for opposition 256 on 19^th Jan 2021	Notification of Possible Opposition Sent
Submitted for opposition 257 on 19^th Mar 2020	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 18^th Mar 2020	Formalized
Submitted for opposition 1 on 18^th Mar 2020	Created
Submitted for opposition 30 on 4^th Mar 2020	Filed
Submitted for opposition 238 on 11^th May 2016	IR Renewed
Submitted for opposition 228 on 11^th May 2006	International Registration